BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO) [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
On April 21, BofA analyst Alec Stranahan reduced the price target on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to $41 from $44, while maintaining a Buy rating on the stock. Stranahan highlighted that Agios intends to seek accelerated approval and has already filed a proposal for a confirmatory trial with an updated primary endpoint. Tonhom1009/Shutterstock.com Nevertheless, the analyst noted that topline results of the HIBISCUS study of Novo Nordisk's etavopivat for sickle cell disease will pose a regulatory risk for Agios' mitapivat. Despite such competitive risks, the stock is still amongst the best oversold small-cap names right now. On April 20, H.C. Wainwright analyst Emily Bodnar reduced the price target on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) from $65 to $50, while maintaining a Buy rating on the stock. She attributed this downward revision to Novo Nordisk's HIBISCUS Phase 3 trial, noting that both primary endpoints were met, which is sure to result in success for sic
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals' (AGIO) Risk-Reward Profile? [Yahoo! Finance]Yahoo! Finance
- Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios (AGIO) Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios (AGIO) Q3 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $44.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- AGIO's page on the SEC website